Enterprise Value
103.2M
Cash
432M
Avg Qtr Burn
-41.19M
Short % of Float
21.96%
Insider Ownership
0.41%
Institutional Own.
67.45%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EDIT-301 Details Genetic disorder, Beta thalessemia | Phase 1/2 Data readout | |
EDIT-301 Details Sickle cell disease, Genetic disorder | Phase 1/2 Data readout | |
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C | Failed Discontinued |